- Home
- DNLI vs LGND Comparison
DNLI vs LGND Comparison
Compare DNLI & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNLI
- LGND
- Stock Information
- Founded
- DNLI 2013
- LGND 1987
- Country
- DNLI United States
- LGND United States
- Employees
- DNLI N/A
- LGND N/A
- Industry
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- LGND Biotechnology: Pharmaceutical Preparations
- Sector
- DNLI Health Care
- LGND Health Care
- Exchange
- DNLI Nasdaq
- LGND Nasdaq
- Market Cap
- DNLI 2.1B
- LGND 2.0B
- IPO Year
- DNLI 2017
- LGND 1992
- Fundamental
- Price
- DNLI $13.89
- LGND $114.07
- Analyst Decision
- DNLI Strong Buy
- LGND Strong Buy
- Analyst Count
- DNLI 15
- LGND 8
- Target Price
- DNLI $33.85
- LGND $144.71
- AVG Volume (30 Days)
- DNLI 1.6M
- LGND 116.0K
- Earning Date
- DNLI 07-31-2025
- LGND 08-05-2025
- Dividend Yield
- DNLI N/A
- LGND N/A
- EPS Growth
- DNLI N/A
- LGND N/A
- EPS
- DNLI N/A
- LGND N/A
- Revenue
- DNLI N/A
- LGND $181,488,000.00
- Revenue This Year
- DNLI N/A
- LGND $18.41
- Revenue Next Year
- DNLI $335.74
- LGND $18.87
- P/E Ratio
- DNLI N/A
- LGND N/A
- Revenue Growth
- DNLI N/A
- LGND 53.40
- 52 Week Low
- DNLI $10.57
- LGND $77.53
- 52 Week High
- DNLI $33.33
- LGND $129.90
- Technical
- Relative Strength Index (RSI)
- DNLI 45.02
- LGND 62.44
- Support Level
- DNLI $14.19
- LGND $111.88
- Resistance Level
- DNLI $14.88
- LGND $116.16
- Average True Range (ATR)
- DNLI 0.77
- LGND 3.58
- MACD
- DNLI -0.03
- LGND 0.89
- Stochastic Oscillator
- DNLI 34.55
- LGND 85.19
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.